Benzimidazole-6-sulfonylurea compound and medical application thereof
By developing benzimidazole-6-sulfonylurea compounds as small molecule GLP-1 receptor agonists, the cAMP signaling pathway is solved, and the problem of inconvenient administration of existing macromolecular peptide drugs is solved. , achieving efficient blood sugar reduction and weight loss effects of oral administration.
Patent Information
- Application Number
- CN202310607992.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-26
- Publication Date
- 2024-11-26
AI Technical Summary
The existing GLP-1 receptor agonists are mainly macromolecular peptide drugs, which require invasive subcutaneous injection. Patients have poor compliance and are difficult to pass through the blood-brain barrier, which cannot effectively reduce appetite, resulting in limited weight loss effect.
Develop a benzimidazole-6-sulfonylurea compound as a small molecule GLP-1 receptor agonist, which activates GLP-1R through the agonist cAMP signaling pathway, with excellent agonism effects, and is used to prepare prevention and treatment with GLP Diseases related to -1R downstream signaling pathway.
It has achieved good bioavailability for oral administration of small molecules, can effectively reduce appetite, and significantly activate GLP-1 receptors, used to treat diseases such as diabetes and metabolic syndrome, and provides better weight loss and blood sugar reduction effects.
Smart Images

Figure BDA0004251538650000021 
Figure BDA0004251538650000022 
Figure BDA0004251538650000041
Abstract
Description
Technical Field
[0001] The invention belongs to the field of pharmaceutical chemistry, and specifically relates to a benzimidazole-6-sulfonylurea compound and its medical use. Background Art
[0002] Diabetes is one of the major diseases that seriously threaten human life and health in modern society. It is caused by an absolute or relative lack of insulin in the human body, which leads to an increase in blood glucose concentration, followed by a large amount of glucose excreted in the urine, and symptoms such as polydipsia, polyuria, polyphagia, and weight loss. According to different pathogenesis, diabetes is mainly divided into type I diabetes and type II diabetes. Decreased pancreatic B cell function and insulin resistance are the main causes of type II diabetes. There are about 425 million diabetic patients in the world. The incidence of diabetes in China is about 10%, of which type II diabetes accounts for 90%, and the prevalence is still increasing, and the age of patients is getting younger. At present, many types of marketed drugs have been used to treat type II diabetes, including insulin, metformin, dipeptidyl peptidase-4 (DPP-IV) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists, α-glucosidase inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, etc. Among them, GLP-1R agonists have the advantages of strong blood sugar reduction, no increased risk of hypoglycemia, weight reduction and mild blood pressure reduction, and their market share has increased significantly in recent years. At the same time, more and more clinical trials have confirmed that GLP-1R agonists have significant therapeutic effects in non-alcoholic fatty liver disease, diabetic nephropathy and Alzheimer's disease.
[0003] Glucagon-like peptide-1 (GLP-1) is a natural peptide incretin hormone secreted by intestinal epithelial L cells. It is widely distributed in the circulatory system and central nervous system, and is rapidly metabolized and cleared by dipeptidyl peptidase-4 (DPP-4) and renal clearance pathways, with a half-life of 1-2 minutes. It binds to its receptor GLP-1R to produce GPCR-related agonist activity mediated by GLP-1R. Studies have shown that GLP-1 promotes insulin secretion in a glucose-dependent manner, and also acts on α cells to inhibit glucagon secretion. When blood glucose concentration in the human body increases, GLP-1 stimulates pancreatic cells, increases insulin secretion, and lowers blood glucose. GLP-1 receptor agonists are a new type of hypoglycemic drug that can effectively control blood glucose levels without causing hypoglycemia; they can also achieve the purpose of weight loss by increasing satiety, delaying gastric emptying, suppressing appetite, and reducing fat accumulation.
[0004] At present, a variety of peptide inhibitors such as liraglutide, exenatide, semaglutide, etc. have been approved for marketing and have cardiovascular health benefits. These peptide agonists have significant hypoglycemic effects, long duration of action, high safety, no serious adverse reactions, and at the same time show significant weight loss effects, cardiovascular protection, relief of non-alcoholic fatty liver disease and central nervous system protection. However, these peptide inhibitors are all based on large molecular peptide drugs and need to be administered by invasive subcutaneous injection. Compared with oral administration, patient compliance is poor. Therefore, small molecule oral GLP-1R agonists, as an alternative, can provide a more standard drug formulation and a simpler method of administration. At the same time, small molecules may pass through the blood-brain barrier and act on the GLP-1R in the arcuate nucleus of the hypothalamus to reduce appetite, which may have a better weight loss effect while lowering blood sugar, so it is of great significance to develop small molecule GLP-1 receptor agonists with good oral bioavailability. Summary of the invention
[0005] The first object of the present invention is to provide a benzimidazole-6-sulfonylurea compound; the second object of the present invention is to provide the use of the benzimidazole-6-sulfonylurea compound, including the use for preparing a GLP-1 receptor agonist and for preparing a drug for preventing and / or treating diseases that are directly or indirectly treated or alleviated by stimulating the GLP-1 receptor.
[0006] The above-mentioned purpose of the present invention is achieved through the following technical solutions:
[0007] A benzimidazole-6-sulfonylurea compound, which is a compound represented by the general formula (I):
[0008]
[0009] in:
[0010] W is the structure shown in W1 or W2:
[0011]
[0012] Ring A is C 3-8 Cycloalkyl, C 2-9 Heterocyclic group, C 5-12 Spirobicyclic, C 5-12 Spiroheterobicyclic, C 5-12 Fused bicyclic group, C 5-12 Fused heterobicyclic group, C 5-12 Bridged ring or C 5-12 bridged heterocyclic group, ring A is optionally substituted by m R 1 replace;
[0013] Ring B is a 6-membered aryl group or a 5- to 6-membered heteroaryl group;
[0014] X1 , X 2 , X 3 and X 4 The same or different, and each independently is -CR 9 or N atoms;
[0015] Y 1 and Y 2 are the same or different and are each independently selected from an O atom, a S atom, -NR 10 and-CR 10 R 11 ;
[0016] L1 is -C(O)-, -O-, -S-, -CR 12 R 13 -or-NR 14 -;
[0017] L2 is selected from -O-, -S-, -NR 15 -and-CR 15 R 16 -;
[0018] R 2 is selected from hydrogen atom, halogen, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, 3-8 membered heterocyclic group, halogenated C1-C6 alkyl, halogenated C1-C6 alkoxy, C3-C8 cycloalkyl substituted C1-C6 alkyl, hydroxy substituted C1-C6 alkyl, C1-C6 alkoxy substituted C1-C6 alkyl, amino substituted C1-C6 alkyl, C1-C6 alkylamino substituted C1-C6 alkyl, C6-C10 aryl, 5-8 membered heteroaryl, nitro, cyano C1-C6 alkyl substituted with hydroxy, C1-C6 alkyl substituted with cyano, hydroxy, -SR, -N(R)2, -C(O)OR, -C(O)N(R)2, -C(O)R, -S(O)2R, -S(O)2N(R)2 and -N(R)C(O)R; each R is independently selected from C1-C6 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C6 alkyl, hydroxy-substituted C1-C6 alkyl, C1-C6 alkoxy-substituted C1-C6 alkyl, amino-substituted C1-C6 alkyl and C1-C6 alkylamino-substituted C1-C6 alkyl;
[0019] R 1 , R 3 , R 6 and R 8are the same or different and are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl are mono- or poly-substituted with one or more substituents selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, cyano, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;
[0020] R 4 and R 5 are the same or different and are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are mono- or poly-substituted with one or more substituents selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;
[0021] R 7 is selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclic, aryl and heteroaryl;
[0022] R 9 , R 10 and R 11 are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclic, aryl and heteroaryl;
[0023] R 12 and R 13 are each independently selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C1-C6 alkoxy, -NR 13a R 13b , 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl and 3-8 membered saturated or partially saturated heterocyclic group, wherein: C1-C6 alkyl or C1-C6 alkoxy is mono- or poly-substituted by one or more substituents selected from halogen, oxo, -CN, -OH and C3-C6 saturated or partially saturated cycloalkyl, and aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclic group is mono- or poly-substituted by one or more substituents selected from halogen, oxo, -CN and -NR 13a R 13b One or more substituents in is mono- or poly-substituted;
[0024] R 14 -H, C1-6 alkyl, C3-10 cycloalkyl, heterocyclic group, -S(O)2R 14a or -S(O)2N(R 14a )(NR 14b ), wherein the cycloalkyl or heterocyclic group is mono- or poly-substituted by one or more substituents selected from C1-6 alkyl, -F or -CN;
[0025] R 15 , R 16 are the same or different and are each independently selected from halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclyl, aryl and heteroaryl;
[0026] R 13a and R 13b Each independently selected from hydrogen and C1-C6 alkyl;
[0027] Each R 14a , R 14b are independently -H, C1-6 alkyl or C3-10 cycloalkyl;
[0028] m is 0, 1, 2, or 3;
[0029] n is 0, 1, 2, 3, 4 or 5;
[0030] o is 0, 1, 2, 3, 4, or 5;
[0031] p is 0, 1, 2 or 3;
[0032] Or it is a pharmaceutically acceptable salt, enantiomer, stereoisomer, hydrate, solvate or polymorph of the compound represented by general formula (I).
[0033] Preferably, the benzimidazole-6-sulfonylurea compound is a compound as shown below:
[0034]
[0035] Or it is a pharmaceutically acceptable salt, enantiomer, stereoisomer, hydrate, solvate or polymorph of the above compound.
[0036] The benzimidazole-6-sulfonylurea compound is used for preparing a GLP-1 receptor agonist.
[0037] The benzimidazole-6-sulfonylurea compound is used for preparing a drug for preventing and / or treating a disease that is directly or indirectly treated or alleviated by stimulating the GLP-1 receptor.
[0038] Preferably, the disease is selected from diabetes, metabolic syndrome, diabetic complications, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, Parkinson's disease, dementia, hyperglycemia, glucose intolerance, atherosclerosis, hypertension, hyperlipidemia, coronary heart disease, cerebral infarction, and cerebral stroke.
[0039] More preferably, the diabetes is type II diabetes.
[0040] A pharmaceutical composition comprises the above-mentioned benzimidazole-6-sulfonylurea compound.
[0041] The above-mentioned pharmaceutical composition is used for preparing a GLP-1 receptor agonist.
[0042] The pharmaceutical composition is used for preparing drugs for preventing and / or treating diseases that are directly or indirectly treated or alleviated by stimulating GLP-1 receptors.
[0043] Preferably, the disease is selected from diabetes, metabolic syndrome, diabetic complications, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, Parkinson's disease, dementia, hyperglycemia, glucose intolerance, atherosclerosis, hypertension, hyperlipidemia, coronary heart disease, cerebral infarction, and cerebral stroke.
[0044] Beneficial effects:
[0045] The present invention provides a class of benzimidazole-6-sulfonylurea compounds, which have a novel structure and can activate the downstream signal transduction of GLP-1R by stimulating the cAMP signal pathway. They have excellent stimulatory effects on the GLP-1 receptor and are excellent GLP-1 receptor agonists. They can be used to prepare drugs for preventing and / or treating diseases or symptoms related to the GLP-1R downstream signal pathway. DETAILED DESCRIPTION
[0046] The essential contents of the present invention are described in detail below in conjunction with the embodiments, but the protection scope of the present invention is not limited thereto.
[0047] Intermediate Int 1 was synthesized according to Scheme 1.
[0048]
[0049] Scheme 1.Reagents and conditions: (a) LiHMDS, THF, N2, -78℃→RT, 4.5h; (b) NaOH,
[0050] MeOH, 60℃, 2h; (c) DCE, 95℃, 4h; (d) Pd2(dba)3,
[0051] 1-(tert-Butyl)-4-methyl-4-(6-chloropyridin-2-yl)piperidin-1,4-dicarboxylate (1a)
[0052] 1-(tert-butyl)4-methyl 4-(6-chloropyridin-2-yl)piperidine-1,4-dicarboxylate(1a)
[0053]
[0054] Dissolve N-Boc-4-piperidinic acid methyl ester (8.3g, 56.5mmol) in tetrahydrofuran, add 34ml of LiHMDS tetrahydrofuran solution (2M), and cool to -78°C under N2 protection. Dissolve the compound 2,6-dichloropyridine (16.5g, 67.8mmol) in tetrahydrofuran and add dropwise. After half an hour of reaction, warm to room temperature and stir for 4.5h. After the reaction is completed by TLC detection, add dilute HCl solution to the reaction solution and adjust the pH to neutral. The reaction solution is extracted with EA, washed twice with saturated sodium chloride solution, and concentrated to obtain a colorless oil (17.5g), which is directly put into the next step.
[0055] 4-(6-Chloropyridin-2-yl)-1-(tert-butyloxycarbonyl)piperidine-4-carboxylic acid (1b)
[0056] 1-(tert-butoxycarbonyl)-4-(6-chloropyridin-2-yl)piperidine-4-carboxylic acid(1b)
[0057]
[0058] The intermediate 1a (17 g) was dissolved in 60 ml of methanol, then added dropwise to a dilute NaOH (2M, 25 ml) solution, heated to 60°C and stirred for 2 h. After the reaction was completed by TLC, a dilute HCl solution was added dropwise to adjust the pH to 2.0, and a white solid precipitated. The white solid 1b (12 g) was obtained by suction filtration and directly used in the next step.
[0059] 4-(6-Chloropyridin-2-yl)piperidine-1-carboxylic acid tert-butyl ester (1c)
[0060] tert-butyl 4-(6-chloropyridin-2-yl)piperidine-1-carboxylate(1c)
[0061]
[0062] The intermediate Int 1b (12 g, 35.3 mmol) was dissolved in 50 ml of dichloroethane and heated to 95°C for 4 h. After the reaction was completed by TLC, the mixture was concentrated to obtain a light yellow oil 1c (8 g, 76.6%). 1 H NMR (300MHz, DMSO-d6) δ7.80(t,J=7.8Hz,1H),7.34(t,J=7.1Hz,2H),4.06(d,J=13.1Hz ,2H),2.92–2.66(m,3H),1.87–1.76(m,2H),1.54(td,J=12.5,4.2Hz,2H),1.41(s,9H).
[0063] tert-Butyl 4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)piperidine-1-carboxylate (1d)
[0064] tert-butyl4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)piperidine-1-carboxylate(1d)
[0065]
[0066] Dissolve the intermediate 1c (8g, 26.3mmol) in 50ml dioxane, add 4-cyano-2-fluorobenzyl alcohol (4.77g, 31.6mmol), Pd2(dba)3 (2.41g, 2.63mmol), X-Phos (2.51g, 5.26mmol), Cs2CO3 (25.7g, 79.0mmol). Stir at 90℃ for 12h under nitrogen protection. After the reaction is completed by TLC detection, the reaction solution is extracted with EA, washed twice with saturated sodium chloride solution, and concentrated. Silica gel column chromatography gives a light yellow oil 1d (4.61g, 42.6%). 1H NMR (300MHz, DMSO-d6) δ7.92–7.82(m,1H),7.75–7.61(m,3H),6.89(d,J=7.3Hz,1H),6.74(d,J=8.2Hz,1H),5.45(s ,2H),4.01(d,J=15.1Hz,2H),2.90–2.66(m,3H),1.73(d,J=12.9Hz,2H),1.50(dt,J=12.5,6.3Hz,2H),1.42(s,9H).
[0067] 3-Fluoro-4-(((6-(piperidin-4-yl)pyridin-2-yl)oxy)methyl)benzonitrile (Int 1)
[0068] 3-fluoro-4-(((6-(piperidin-4-yl)pyridin-2-yl)oxy)methyl)benzonitrile(Int 1)
[0069]
[0070] Intermediate 1d (4.61 g, 11.2 mmol) was dissolved in 40 ml EA, and then pTSA·H2O (4.68 g, 24.6 mmol) was added, and the mixture was heated to 60°C and stirred for 2 h, and a white solid precipitated. After the reaction was completed by TLC detection, the reaction solution was filtered to obtain a white solid Int 1 (5 g, 65.2%). 1 H NMR (300MHz, DMSO-d6) δ8.54(s,1H),8.27(s,1H),7.92(d,J=10.0Hz,1H),7.77–7.65(m,3H),7.48(d,J=8.1Hz,4H),7.12(d,J=7.8Hz,4H),6.90(d,J =7.3Hz,1H),6.79(d,J=8.2Hz,1H),5.48(s,2H),3.38(s,1H),3.04(d,J=1 2.0Hz, 1H), 2.93 (dd, J=21.8, 11.1Hz, 2H), 2.29 (s, 6H), 2.01–1.73 (m, 4H).
[0071] Examples 1-6 were synthesized according to Scheme 2.
[0072]
[0073] Scheme 2.Reagents and conditions:(a)LiHMDS,Dry ACN, -78℃→0℃, 2h; (b) DIPEA, ACN, 60℃, 4h; (c) H2, Pd-C, CH3OH, 50℃, 6h; (d) pTSA, ACN, 60℃, 4h; (e) K2CO3, ACN, 50℃, 2h; (f) CF3COOH, DCM, rt, 2h; (g) DBU, ACN, rt, 2h.
[0074] Tert-butyl ((3-fluoro-4-nitrophenyl)sulfonyl)carbamate (1-1)
[0075] tert-butyl((3-fluoro-4-nitrophenyl)sulfonyl)carbamate(1-1)
[0076]
[0077] Dissolve tert-butyl carbamate (10.74g, 91.7mmol) in 100ml of anhydrous acetonitrile and cool to -78°C under N2 protection. Dissolve compound 3-fluoro-4-nitrobenzenesulfonyl chloride (18.26g, 76.4mmol) in 150ml of anhydrous acetonitrile and add quickly. After half an hour of reaction, warm to room temperature and stir for 1.5h. After the reaction is completed by TLC detection, add dilute HCl solution to the reaction solution and adjust the pH to neutral. The reaction solution is extracted three times with equal volumes of ethyl acetate and water, the organic layers are combined and concentrated at low pressure to remove the solvent, and the residue is subjected to column chromatography to obtain intermediate 1-1 (10.47g, 42.8%). 1 H NMR (300MHz, DMSO-d6) δ8.19 (dd, J = 8.8, 7.3Hz, 1H), 7.78–7.65 (m, 2H), 1.22 (s, 9H).
[0078] (S)-tert-Butyl ((4-nitro-3-((oxetanylamino-2-ylmethyl)amino)phenyl)sulfonyl)carbamate (1-2)
[0079] tert-butyl(S)-((4-nitro-3-((oxetan-2-ylmethyl)amino)phenyl)sulfonyl)carbamate(1-2)
[0080]
[0081] Dissolve the intermediate 1-1 (10.47 g, 32.71 mmol) in 50 ml of acetonitrile, add DIPEA (6.83 ml, 39.25 mmol) and (S)-oxetane-2-ylmethylamine (3.42 g, 39.25 mmol), and heat to 60 ° C for 4 h. After the reaction is completed by TLC detection, saturated ammonium chloride solution is added to quench. The reaction solution is extracted three times with equal volumes of ethyl acetate and water, the organic layers are combined and concentrated under low pressure to remove the solvent, and the residue is subjected to column chromatography to obtain intermediate 1-2 (9.18 g, 72.5%). 1 H NMR (300MHz, DMSO-d6) δ8.41(t,J=5.7Hz,1H),8.19(d,J=8.9Hz,1H),7.49(d,J=1.8Hz,1H),7.01(dd,J=9.0,1. 8Hz,1H),5.00(t,J=5.9Hz,1H),4.62–4.39(m,2H),3.72–3.57(m,3H),2.76–2.52(m,2H),1.26(d,J=9.3Hz,9H).
[0082] (S)-tert-Butyl ((4-amino-3-((oxetanylamino-2-ylmethyl)amino)phenyl)sulfonyl)carbamate (1-3)
[0083] tert-butyl(S)-((4-amino-3-((oxetan-2-ylmethyl)amino)phenyl)sulfonyl)carbamate(1-3)
[0084]
[0085] Dissolve intermediate 1-2 (9.18 g, 23.72 mmol) in 40 ml methanol, add 10% Pd-C (918 mg), and heat to 50°C under N2 protection for 2 h. After the reaction is completed by TLC, filter the reaction solution with diatomaceous earth and concentrate under low pressure to remove the solvent. The residue is subjected to column chromatography to obtain intermediate 1-3 (5.1 g, 60.2%). 1H NMR (300MHz, DMSO-d6) δ11.01(s,1H),6.99(dd,J=8.2,2.1Hz,1H),6.86(d,J=2.1Hz,1H),6.58(d,J=8.2Hz,1H),5.60(s,2H),4.95(dt,J=14 .1,6.0Hz,2H),4.61–4.41(m,2H),3.31(ddt,J=18.9,13.2,6.9Hz,2H),2.67(dtd,J=10.9,8.1,6.2Hz,1H),2.50–2.35(m,1H),1.30(s,9H).
[0086] (S)-tert-Butyl ((2-(chloromethyl)-1-(oxetanylamino-2-ylmethyl)-1H-benzo[d]imidazol-6-yl)sulfonyl)carbamate (1-4)
[0087] tert-butyl
[0088] (S)-((2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazol-6-yl)sulfonyl)carbamate(1-4)
[0089]
[0090] Dissolve the intermediate 1-3 (5.1 g, 14.24 mmol) in 30 ml of acetonitrile, add p-toluenesulfonic acid hydrate (2.4 g, 1.42 mmol) and 2-chloro-1,1,1-trimethoxyethane (2.63 g, 17.09 mmol), and heat to 60°C for 4 h. After the reaction is completed by TLC, the reaction solution is extracted three times with equal volumes of ethyl acetate and water, the organic layers are combined and concentrated under low pressure to remove the solvent, and the residue is subjected to column chromatography to obtain the intermediate 1-4 (2.4 g, 40.6%). 1HNMR(300MHz,DMSO-d6)δ11.64(s,1H),8.30(d,J=1.8Hz,1H),7.88(d,J=8.6Hz,1H) ,7.74(dd,J=8.6,1.8Hz,1H),5.21–5.09(m,2H),5.05(td,J=7.2,2.7Hz,1H),4.79( dd,J=15.5,6.9Hz,1H),4.67(dd,J=15.5,2.9Hz,1H),4.47(td,J=8.1,7.7,5.8Hz,1 H), 4.32 (dt, J = 9.1, 5.9 Hz, 1H), 2.79–2.61 (m, 1H), 2.46–2.29 (m, 1H), 1.27 (s, 9H).
[0091] (S)-tert-Butyl ((2-((4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxetanylamino-2-ylmethyl)-1H-benzo[d]imidazol-6-yl)sulfonyl)carbamate (1-5)
[0092] tert-butyl
[0093] (S)-((2-((4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmet hyl)-1H-benzo[d]imidazol-6-yl)sulfonyl)carbamate(1-5)
[0094]
[0095] Dissolve intermediate 1-4 (2.4 g, 5.79 mmol) in 15 ml acetonitrile, add intermediate Int 1 (4.76 g, 6.95 mmol), K2CO3 (4 g, 28.95 mmol), and heat to 50 ° C for 2 h. After the reaction is completed by TLC detection, add saturated ammonium chloride solution to quench. The reaction solution is extracted three times with equal volumes of ethyl acetate and water, the organic layers are combined and concentrated under low pressure to remove the solvent, and the residue is subjected to column chromatography to obtain intermediate 1-5 (3 g, 75.1%). 1HNMR(300MHz,DMSO-d6)δ11.53(s,1H),8.23(d,J=1.8Hz,1H),7.95–7.86(m,jj 1H),7.85–7.60(m,5H),6.89(d,J=7.3Hz,1H),6.73(d,J=8.2Hz,1H),5.47(s,2H),5.11 (d,J=7.2Hz,1H),4.82(dd,J=15.3,6.9Hz,1H),4.70(d,J=14.7Hz,1H),4.55–4.30(m,2 H),4.06–3.93(m,2H),3.92–3.79(m,1H),3.02(d,J=10.8Hz,1H),2.93–2.81(m,1H),2. 77–2.57(m,2H),2.35–2.25(m,1H),2.27–2.17(m,1H),1.79–1.61(m,4H),1.27(s,9H).
[0096] (S)-2-((4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxetanylamino-2-ylmethyl)-1H-benzo[d]imidazole-6-sulfonamide (1-6)
[0097] (S)-2-((4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxetan-2-yl methyl)-1H-benzo[d]imidazole-6-sulfonamide(1-6)
[0098]
[0099] Dissolve intermediate 1-5 (3 g, 4.33 mmol) in 20 ml of dichloromethane, add CF3COOH (4.93 g, 43.3 mmol) dropwise, and stir at room temperature for 2 h. After the reaction is completed by TLC, add saturated sodium bicarbonate solution to quench. The reaction solution is extracted three times with equal volumes of ethyl acetate and water, the organic layers are combined and concentrated under low pressure to remove the solvent, and the residue is subjected to column chromatography to obtain intermediate 1-6 (2.18 g, 85.4%). 1H NMR(300MHz, DMSO-d6)δ8.15(d,J=1.7Hz,1H),7.95–7.86(m,1H),7.80–7.60(m,5H),7.31(s,2H),6.89(d,J= 7.3Hz,1H),6.73(d,J=8.2Hz,1H),5.47(s,2H),5.12(dd,J=7.2,2.9Hz,1H),4.80(dd,J=15.2,7.1Hz,1H),4. 67(dd,J=15.2,3.1Hz,1H),4.56–4.33(m,2H),4.00–3.94(m,1H),3.85–3.79(m,1H),3.03–2.95(m,1H),2.89 –2.82(m,1H),2.80–2.63(m,1H),2.63–2.57(m,1H),2.25–2.17(m,1H),1.80–1.65(m,3H),1.35–1.20(m,1H).
[0100] Embodiment 1:
[0101] (S)-2-((4-(6-((4-nitrile-2-fluorobenzyl)oxy)pyridin-2-yl)piperazin-1-yl)methyl)-N-(methylcarbamoyl)-1-(oxetan-2-ylmethyl)-1H-benzimidazole-6-sulfonamide
[0102] (S)-2-((4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-N-(methylcarb amoyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-sulfonamide
[0103]
[0104] Dissolve the intermediate 1-6 (300 mg, 0.51 mmol) in 5 ml of acetonitrile, add N-methylcarbamic acid phenyl ester (84.6 mg, 0.56 mmol) and DBU (85.3 mg, 0.56 mmol), and stir at room temperature for 2 h. After the reaction is completed by TLC detection, add saturated ammonium chloride solution to quench. The reaction solution is extracted three times with equal volumes of ethyl acetate and water, the organic layers are combined and concentrated under low pressure to remove the solvent, and the residue is subjected to column chromatography to obtain the target product Example 1 (290.1 mg, 88.2%). 1H NMR (300MHz, DMSO-d6) δ10.66(s,1H),8.25(s,1H),7.89(d,J=9.9Hz,1H),7.78(d,J=8.5Hz,1H),7.72–7.62(m,4H),6.89( d,J=7.3Hz,1H),6.72(d,J=8.2Hz,1H),6.38(d,J=6.0Hz,1H),5.47(s,2H),4.95–5.19(m,1H),4.81(dd,J=15.2,6.9Hz,1H ),4.69(d,J=14.9Hz,1H),4.49(d,J=7.3Hz,1H),4.38(d,J=7.1Hz,1H),3.98(d,J=13.6Hz,1H),3.92–3.76(m,1H),2.99(d ,J=11.0Hz,1H),2.86(d,J=10.9Hz,1H),2.68(d,J=19.2Hz,1H),2.47–2.35(m,1H),2.27–2.12(m,2H),1.81–1.63(m,4H). HRMS(ESI):calcd for C 32 H 34 FN7O5S,[M+H] + 648.2326, found 648.2372. Purity: 93.89% by HPLC (MeOH:H2O with 1‰TEA=70:30, t R =5.96min).
[0105] Embodiment 2:
[0106] (S)-2-((4-(6-((4-nitrile-2-fluorobenzyl)oxy)pyridin-2-yl)piperazin-1-yl)methyl)-N-(ethylcarbamoyl)-1-(oxetanylamino-2-ylmethyl)-1H-benzimidazole-6-sulfonamide
[0107] (S)-2-((4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-N-(ethylcarba moyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-sulfonamide
[0108]
[0109] Dissolve the intermediate 1-6 (300 mg, 0.51 mmol) in 5 ml of acetonitrile, add N-ethylcarbamic acid phenyl ester (92.4 mg, 0.56 mmol) and DBU (85.3 mg, 0.56 mmol), and stir at room temperature for 2 h. After the reaction is completed by TLC detection, add saturated ammonium chloride solution to quench. The reaction solution is extracted three times with equal volumes of ethyl acetate and water, the organic layers are combined and concentrated under low pressure to remove the solvent, and the residue is subjected to column chromatography to obtain the target product Example 2 (272.5 mg, 81.1%). 1 H NMR (300MHz, DMSO-d6) δ10.57(s,1H),8.25(d,J=1.8Hz,1H),7.95–7.86(m,1H),7.78(d,J=8.6Hz,1H),7.74–7.60(m,4H),6 .89(d,J=7.3Hz,1H),6.73(d,J=8.2Hz,1H),6.47(t,J=5.7Hz,1H),5.47(s,2H),5.16–5.07(m,1H),4.82(dd,J=15.2,7.1Hz, 1H),4.75–4.64(m,1H),4.55–4.32(m,2H),3.97(d,J=13.6Hz,1H),3.80(d,J=13.6Hz,1H),3.03–2.88(m,3H),2.90–2.80(m ,1H),2.80–2.65(m,1H),2.62–2.56(m,1H),2.48–2.42(m,1H),2.31–2.11(m,2H),1.82–1.60(m,4H),0.92(t,J=7.2Hz,3H). HRMS(ESI):calcd for C 33 H 36 FN7O5S,[M+H] + 662.2483,found661.2491. Purity: 92.51% by HPLC (MeOH:H2O with 1‰TEA=70:30,t R =5.76min).
[0110] Embodiment 3:
[0111] (S)-2-((4-(6-((4-nitrile-2-fluorobenzyl)oxy)pyridin-2-yl)piperazin-1-yl)methyl)-N-(propylcarbamoyl)-1-(oxetan-2-ylmethyl)-1H-benzimidazole-6-sulfonamide
[0112] (S)-2-((4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-N-(propylcarbamoyl)-1H-benzo[d]imidazole-6-sulfonamide
[0113]
[0114] Dissolve the intermediate 1-6 (300 mg, 0.51 mmol) in 5 ml of acetonitrile, add N-propylcarbamic acid phenyl ester (100.2 mg, 0.56 mmol) and DBU (85.3 mg, 0.56 mmol), and stir at room temperature for 2 h. After the reaction is completed by TLC detection, add saturated ammonium chloride solution to quench. The reaction solution is extracted three times with equal volumes of ethyl acetate and water, the organic layers are combined and concentrated under low pressure to remove the solvent, and the residue is subjected to column chromatography to obtain the target product Example 3 (279.7 mg, 81.5%). 1 H NMR (300MHz, DMSO-d6) δ10.53(s,1H),8.25(d,J=1.7Hz,1H),7.91(d,J=9.9Hz,1H),7.78(d,J=8.5Hz,1H),7.74–7.60(m,4H),6.89(d,J=7. 3Hz,1H),6.73(d,J=8.1Hz,1H),6.47(t,J=5.7Hz,1H),5.47(s,2H),5.18–5.07(m,1H),4.82(dd,J=15.2,7.1Hz,1H),4.69(d,J=15.5Hz,1H ),4.49(q,J=7.3Hz,1H),4.38(dt,J=8.8,6.0Hz,1H),3.98(d,J=13.6Hz,1H),3.81(d,J=13.6Hz,1H),3.04–2.94(m,1H),2.95–2.77(m,3H) ,2.77–2.65(m,1H),2.65–2.53(m,1H),2.49–2.35(m,1H),2.31–2.10(m,2H),1.81–1.60(m,4H),1.37–1.21(m,2H),0.72(t,J=7.4Hz,3H). HRMS(ESI):calcd for C 34 H 38 FN7O5S,[M+H] +676.2639, found 676.2664. Purity: 93.22% by HPLC (MeOH:H2O with 1‰TEA=70:30,t R =5.59min).
[0115] Embodiment 4:
[0116] (S)-2-((4-(6-((4-nitrile-2-fluorobenzyl)oxy)pyridin-2-yl)piperazin-1-yl)methyl)-N-(isopropylcarbamoyl)-1-(oxetanylamino-2-ylmethyl)-1H-benzimidazole-6-sulfonamide
[0117] (S)-2-((4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-N-(isopropylcarbamoyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-sulfonamide
[0118]
[0119] Dissolve the intermediate 1-6 (300 mg, 0.51 mmol) in 5 ml of acetonitrile, add N-isopropylphenylcarbamate (100.2 mg, 0.56 mmol) and DBU (85.3 mg, 0.56 mmol), and stir at room temperature for 2 h. After the reaction is completed by TLC detection, add saturated ammonium chloride solution to quench. The reaction solution is extracted three times with equal volumes of ethyl acetate and water, the organic layers are combined and concentrated under low pressure to remove the solvent, and the residue is subjected to column chromatography to obtain the target product Example 4 (294.5 mg, 85.8%). 1H NMR (300MHz, DMSO-d6) δ10.37(s,1H),8.25(d,J=1.7Hz,1H),7.95–7.85(m,1H),7.78(d,J=8.6Hz,1H),7.73–7.60(m,3H),6.89(d,J=7.3H z,1H),6.73(d,J=8.2Hz,1H),6.29(d,J=7.6Hz,1H),5.47(s,2H),5.16–5.07(m,1H),4.82(dd,J=15.1,7.0Hz,1H),4.69(dd,J=15.0,2.9Hz ,1H),4.55–4.43(m,1H),4.43–4.31(m,1H),3.99(d,J=13.6Hz,1H),3.82(d,J=13.6Hz,1H),3.56(h,J=6.6Hz,1H),3.05–2.95(m,1H),2.91 –2.81(m,1H),2.77–2.65(m,1H),2.63–2.57(m,1H),2.48–2.36(m,1H),2.33–2.12(m,2H),1.83–1.56(m,4H),0.98(dd,J=6.5,2.2Hz,6H). HRMS(ESI):calcd for C 34 H 38 FN7O5S,[M+H] + 676.2639, found 676.2614. Purity: 95.89% by HPLC (MeOH:H2O with 1‰TEA=70:30,t R =5.45min).
[0120] Embodiment 5:
[0121] (S)-2-((4-(6-((4-nitrile-2-fluorobenzyl)oxy)pyridin-2-yl)piperazin-1-yl)methyl)-N-(cyclopropylcarbamoyl)-1-(oxetanylamino-2-ylmethyl)-1H-benzimidazole-6-sulfonamide
[0122] (S)-2-((4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-N-(cyclopropyl carbamoyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-sulfonamide
[0123]
[0124] Dissolve the intermediate 1-6 (300 mg, 0.51 mmol) in 5 ml of acetonitrile, add N-cyclopropylcarbamic acid phenyl ester (99.1 mg, 0.56 mmol) and DBU (85.3 mg, 0.56 mmol), and stir at room temperature for 2 h. After the reaction is completed by TLC detection, add saturated ammonium chloride solution to quench. The reaction solution is extracted three times with equal volumes of ethyl acetate and water, the organic layers are combined and concentrated under low pressure to remove the solvent, and the residue is subjected to column chromatography to obtain the target product Example 5 (271.8 mg, 79.4%). 1 H NMR (300MHz, DMSO-d6) δ10.48(s,1H),8.24(d,J=1.7Hz,1H),7.95–7.86(m,1H),7.78(d,J=8.5Hz,1H),7.75–7.60(m,4H),6.89(d,J=7.3Hz,1 H),6.73(d,J=8.2Hz,1H),6.60(d,J=6.9Hz,1H),5.47(s,2H),5.12(dd,J=7.7,2.7Hz,1H),4.82(dd,J=15.1,7.1Hz,1H),4.69(dd,J=15.2,3.1 Hz,1H),4.49(q,J=7.7,7.2Hz,1H),4.39(dt,J=8.8,5.9Hz,1H),3.99(d,J=13.6Hz,1H),3.82(d,J=13.6Hz,1H),3.05–2.95(m,1H),2.91–2.81 (m,1H),2.80–2.66(m,1H),2.62–2.56(m,1H),2.48–2.34(m,1H),2.31 –2.12(m,2H),1.84–1.61(m,4H),0.60–0.48(m,2H),0.38–0.26(m,2H). HRMS(ESI):calcd for C 34 H 36 FN7O5S,[M+H] + 674.2483,found674.2492. Purity: 94.21% by HPLC (MeOH:H2O with 1‰TEA=70:30,t R =5.67min).
[0125] Embodiment 6:
[0126] (S)-2-((4-(6-((4-nitrile-2-fluorobenzyl)oxy)pyridin-2-yl)piperazin-1-yl)methyl)-N-(cyclopentylcarbamoyl)-1-(oxetanylamino-2-ylmethyl)-1H-benzimidazole-6-sulfonamide
[0127] (S)-2-((4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-N-(cyclopentyl carbamoyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-sulfonamide
[0128]
[0129] Dissolve the intermediate 1-6 (300 mg, 0.51 mmol) in 5 ml of acetonitrile, add N-cyclopentylcarbamic acid phenyl ester (114.8 mg, 0.56 mmol) and DBU (85.3 mg, 0.56 mmol), and stir at room temperature for 2 h. After the reaction is completed by TLC detection, add saturated ammonium chloride solution to quench. The reaction solution is extracted three times with equal volumes of ethyl acetate and water, the organic layers are combined and concentrated under low pressure to remove the solvent, and the residue is subjected to column chromatography to obtain the target product Example 6 (294.2 mg, 82.5%). 1 H NMR (300MHz, DMSO-d6) δ11.58(s,1H),8.22(s,1H),7.91(d,J=9.9Hz,1H),7.79(d,J=8.4Hz,1H),7.74–7.63(m,4H),6.89(d ,J=7.3Hz,1H),6.73(d,J=8.3Hz,1H),6.42(d,J=7.2Hz,1H),5.47(s,2H),5.15–5.08(m,1H),4.88–4.75(m,1H),4.69(dd,J =15.3,2.9Hz,1H),4.47(t,J=7.4Hz,1H),4.39(dt,J=8.9,5.9Hz,1H),3.98(d,J=13.6Hz,1H),3.86–3.66(m,2H),3.04–2.9 4(m,1H),2.90–2.80(m,1H),2.77–2.68(m,1H),2.47–2.37(m,1H),2.31–2.11(m,2H),1.79–1.60(m,7H),1.58–1.39(m,5H). HRMS(ESI):calcd for C 36 H 40FN7O5S,[M+H] + 702.2796,found702.2784. Purity: 95.02% by HPLC (MeOH:H2O with 1‰TEA=70:30,t R =5.80min).
[0130] Effect Example: Evaluation of GLP-1 receptor cAMP agonist activity
[0131] 1. Experimental Materials and Methods
[0132] 1. Experimental reagents and instruments
[0133] Table 1 Experimental reagents and consumables
[0134]
[0135] Table 2 Experimental instruments and devices
[0136]
[0137] 2. Experimental cells
[0138] We used a HEK cell line that stably expresses GLP-1R (constructed by Beijing Aisi Yipu Biotechnology Co., Ltd., expressing the human GLP-1R gene), and the number of cells used for the test was 1000 / well. The cell lines were cultured in DMEM + 100μg / mL Hygromycin B medium containing 10% fetal bovine serum, the culture temperature was 37℃, and the carbon dioxide concentration was 5%. The old culture medium was removed and washed once with PBS, and then 1mL Cell Dissociation Buffer solution was added and incubated at 37℃ for about 2min. When the cells detached from the bottom of the dish, about 2mL of complete culture medium preheated at 37℃ was added. The cell suspension was gently blown with a pipette to separate the aggregated cells. The cell suspension was transferred to a sterile centrifuge tube and centrifuged at 1000rpm for 5min to collect the cells for experiments or subculture. In order to maintain the physiological activity of the cells, the experimental cell confluence was controlled at about 80%. Cell subculture, recovery and cryopreservation were performed according to conventional methods. All operations followed the standard operating procedures for cell culture of Beijing Aisi Yipu Biotechnology Co., Ltd.
[0139] 3. Experimental methods
[0140] The test used the LANCE Ultra cAMPkit.
[0141] Step 1: All reagents in the kit should be equilibrated to room temperature before use. Prepare 1× Stimulation Buffer according to the kit instructions.
[0142] Step 2: The compound was diluted with DMSO in a gradient manner, and then diluted to 10× with 1×Stimulation Buffer. The actual starting test concentration was set to 5000nM, and 10 groups were diluted in a 5-fold gradient, where each test group contained 2 sets of duplicate test wells. Each test group was set with a DMSO concentration of 0.1% as the negative control group, and a GLP-1 (7-37) concentration of 100nM as the positive control group.
[0143] Step 3: Stably transfected cells were cultured to 80% confluency; cells were digested and collected with Cell Dissociation Buffer solution, and after counting, 9 μL / well was inoculated into a 384-well plate.
[0144] Step 4: Take 1 μL of the 10× compound diluted in step 2 and add it to the corresponding experimental well. After centrifugation, incubate at 37°C for 30 min.
[0145] Step 5: Dilute Eu-cAMP to the working concentration with detection buffer and add 5 μL / well to the corresponding experimental wells.
[0146] Step 6: Dilute ULight-anti-cAMP to the working concentration with detection buffer, then add 5 μL / well to the corresponding experimental wells; centrifuge and incubate at room temperature for 1 hour.
[0147] Step 7: After incubation, use the Biotek multifunctional microplate reader to detect the readings at 665nm and 620nm. Calculate the ratio of the readings at the corresponding wavelength conditions, R 665 / 620 , calculate the average ratio (R Group ), positive reference average ratio
[0148] ——
[0149] (R GLP-1(7-37) ) and negative reference mean ratio (R DMSO ), the excitation rate A was calculated according to the formula, the excitation effect of the compound at the 5000nM level was determined, and the compound with excitation effect (A 5000nM >50.00%). The A of the compound test concentration with an agonistic effect greater than 80% was selected and plotted against the corresponding concentration. The curve fitting and half agonist activity concentration (EC) were calculated using the nonlinear regression method of GraphPadPrism software. 50 )calculate.
[0150] 2. Experimental Results
[0151] Table 3 EC of compounds for agonism of cAMP signal 50
[0152]
[0153] The test results show that the compounds of the present invention can activate the downstream signal transduction of GLP-1R by stimulating the cAMP signaling pathway and have an excellent stimulating effect on the GLP-1 receptor.
[0154] The purpose of the above-mentioned embodiments is to specifically introduce the essential content of the present invention, but those skilled in the art should know that the protection scope of the present invention should not be limited to the specific embodiments.
Claims
1. A benzimidazole-6-sulfonylurea compound, which is a compound represented by the general formula (I): in: W is the structure shown in W1 or W2: Ring A is C 3-8 Cycloalkyl, C 2-9 Heterocyclic group, C 5-12 Spirobicyclic, C 5-12 Spiroheterobicyclic, C 5-12 Fused bicyclic group, C 5-12 Fused heterobicyclic group, C 5-12 Bridged ring or C 5-12 bridged heterocyclic group, ring A is optionally substituted by m R 1 replace; Ring B is a 6-membered aryl group or a 5- to 6-membered heteroaryl group; X 1 , X 2 , X 3 and X 4 The same or different, and each independently is -CR 9 or N atoms; Y 1 and Y 2 are the same or different and are each independently selected from an O atom, a S atom, -NR 10 and-CR 10 R 11 ; L1 is -C(O)-, -O-, -S-, -CR 12 R 13 -or-NR 14 -; L2 is selected from -O-, -S-, -NR 15 -and-CR 15 R 16 -; R 2 is selected from hydrogen atom, halogen, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, 3-8 membered heterocyclic group, halogenated C1-C6 alkyl, halogenated C1-C6 alkoxy, C3-C8 cycloalkyl substituted C1-C6 alkyl, hydroxy substituted C1-C6 alkyl, C1-C6 alkoxy substituted C1-C6 alkyl, amino substituted C1-C6 alkyl, C1-C6 alkylamino substituted C1-C6 alkyl, C6-C10 aryl, 5-8 membered heteroaryl, nitro, cyano C1-C6 alkyl substituted with hydroxy, C1-C6 alkyl substituted with cyano, hydroxy, -SR, -N(R)2, -C(O)OR, -C(O)N(R)2, -C(O)R, -S(O)2R, -S(O)2N(R)2 and -N(R)C(O)R; each R is independently selected from C1-C6 alkyl, C3-C8 cycloalkyl, halo-substituted C1-C6 alkyl, hydroxy-substituted C1-C6 alkyl, C1-C6 alkoxy-substituted C1-C6 alkyl, amino-substituted C1-C6 alkyl and C1-C6 alkylamino-substituted C1-C6 alkyl; R 1 , R 3 , R 6 and R 8 are the same or different and are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl are mono- or poly-substituted with one or more substituents selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, cyano, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; R 4 and R 5 are the same or different and are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are mono- or poly-substituted with one or more substituents selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; R 7 is selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclic, aryl and heteroaryl; R 9 , R 10 and R 11 are the same or different and are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclic, aryl and heteroaryl; R 12 and R 13 are each independently selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C1-C6 alkoxy, -NR 13a R 13b , 6-10 membered aryl, 5-8 membered heteroaryl, 3-8 membered saturated or partially saturated cycloalkyl and 3-8 membered saturated or partially saturated heterocyclic group, wherein: C1-C6 alkyl or C1-C6 alkoxy is mono- or poly-substituted by one or more substituents selected from halogen, oxo, -CN, -OH and C3-C6 saturated or partially saturated cycloalkyl, and aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclic group is mono- or poly-substituted by one or more substituents selected from halogen, oxo, -CN and -NR 13a R 13b One or more substituents in is mono- or poly-substituted; R 14 -H, C1-6 alkyl, C3-10 cycloalkyl, heterocyclic group, -S(O)2R 14a or -S(O)2N(R 14a )(NR 14b ), wherein the cycloalkyl or heterocyclic group is mono- or poly-substituted by one or more substituents selected from C1-6 alkyl, -F or -CN; R 15 , R 16 are the same or different and are each independently selected from halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclyl, aryl and heteroaryl; R 13a and R 13b Each independently selected from hydrogen and C1-C6 alkyl; Each R 14a , R 14b are independently -H, C1-6 alkyl or C3-10 cycloalkyl; m is 0, 1, 2, or 3; n is 0, 1, 2, 3, 4 or 5; o is 0, 1, 2, 3, 4, or 5; p is 0, 1, 2 or 3; Or it is a pharmaceutically acceptable salt, enantiomer, stereoisomer, hydrate, solvate or polymorph of the compound represented by general formula (I).
2. The benzimidazole-6-sulfonylurea compound according to claim 1 is a compound as shown below: Or it is a pharmaceutically acceptable salt, enantiomer, stereoisomer, hydrate, solvate or polymorph of the above compound.
3. Use of the benzimidazole-6-sulfonylurea compound according to claim 1 or 2 for preparing a GLP-1 receptor agonist.
4. Use of the benzimidazole-6-sulfonylurea compound according to claim 1 or 2 for preparing a drug for preventing and / or treating a disease that is directly or indirectly treated or alleviated by stimulating the GLP-1 receptor.
5. The use according to claim 4, wherein the disease is selected from diabetes, metabolic syndrome, diabetic complications, obesity, non-alcoholic fatty liver disease, non-alcoholic fatty hepatitis, Parkinson's disease, dementia, hyperglycemia, glucose intolerance, atherosclerosis, hypertension, hyperlipidemia, coronary heart disease, cerebral infarction, and cerebral stroke. The use according to claim 5, wherein the diabetes is type II diabetes.
7. A pharmaceutical composition comprising the benzimidazole-6-sulfonylurea compound according to claim 1 or 2.
8. Use of the pharmaceutical composition according to claim 7 for preparing a GLP-1 receptor agonist.
9. Use of the pharmaceutical composition according to claim 7 for preparing a drug for preventing and / or treating a disease that is directly or indirectly treated or alleviated by stimulating the GLP-1 receptor.
10. The use according to claim 9, wherein the disease is selected from diabetes, metabolic syndrome, diabetic complications, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, Parkinson's disease, dementia, hyperglycemia, glucose intolerance, atherosclerosis, hypertension, hyperlipidemia, coronary heart disease, cerebral infarction, and cerebral stroke.
